Benefit of early sustained reperfusion in patients with prior myocardial infarction (The GUSTO-I Trial)

American Journal of Cardiology

Volumn 81, Issue 3, 1998, Pages 282-287

  Brieger, David B ^b   Mak, Koon Hou ^b   White, Harvey D ^b   Kleiman, Neal S ^b   Miller, David P ^b   Vahanian, Alec ^b   Ross, Allan M ^b   Califf, Robert M ^b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMERGENCY HEALTH SERVICE; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032006782     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00909-0     Document Type: Article

References (11)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1:1986;397-401.
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. 2:1988;349-360.
3. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients . Lancet. 343:1994;311-322.
4. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
5. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, Califf RM. Stroke after thrombolysis Mortality and functional outcomes in the GUSTO-1 trial . Circulation. 92:1995;2811-2818.
6. Chesebro JH, Knatterud G, Roberts R. Thrombolysis in Myocardial Infarction Trial, Phase 1 a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge . Circulation. 76:1987;142-154.
7. Dodge HT, Sandler H, Ballew DW, Lord JD. The use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J. 60:1960;762-776.
8. Lee KL, Woodlief LH, Topol EJ, Weaver D, Betriu A, Col J, Simoons M, Aylward P, Van der Werf F, Califf RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction Results from an international trial of 41021 patients . Circulation. 91:1995;1659-1668.
9. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
10. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Keriakes D, George B, Stack R. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 82:1990;781-791.
11. Brouwer MA, Bohncke JR, Veen G, Meijer A, Van Eenige MJ, Verheught FW. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol. 26:1995;1440-1444.